Compass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression
Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA
Compass Pathways announced it has submitted a new drug application to the FDA for its COMP360 psilocybin for treatment-resistant depression (TRD). The FDA is now reviewing three psychedelic applications, after Resilient Pharmaceuticals resubmitted its MDMA for PTSD application this summer and Usona Institute filed its psilocybin for major depressive disorder (MDD) package more recently. Compass said its package includes data from more than 1,000 participants, and the company is targeting an H1 2027 launch.
With three psychedelic applications now before the FDA, the agency's next steps on COMP360 will show how it handles a package drawn from more than 1,000 participants.
Key facts
- Kind of item
- Trial registrations
- Compound
- Psilocybin
- Condition
- Depression
- Organisation
- Compass Pathways
- Regulator
- FDA (United States)
- Jurisdiction
- United States
- Participants
- more than 1,000 participants (as written in the text)
- Source
- Psychedelic Alpha (psychedelicalpha.com)
- Published
- Original
- Read it at psychedelicalpha.com
How this summary was made
The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: Psychedelic Alpha · psychedelicalpha.com
Connected to
- Kind of item
- Trial registrations
- Compound
- Psilocybin
- Condition
- Depression
- Organisation
- Compass Pathways
- Regulator
- FDA (United States)
- Jurisdiction
- United States